Praxis Medical Insights

Pathophysiology and Clinical Significance

The thymus is the primary site where autoimmunity develops in myasthenia gravis, with 30-50% of patients having thymomas and most others showing thymic hyperplasia with germinal centers that produce the pathogenic anti-acetylcholine receptor antibodies, according to the National Comprehensive Cancer Network 1, 2
Thymoma is present in 30-50% of myasthenia gravis patients, making it a major risk factor for disease development, as reported by the National Comprehensive Cancer Network and other sources 1, 2, 4
Approximately 20% of thymoma-related mortality in myasthenia gravis patients is directly attributable to the myasthenia gravis itself, not the tumor, as stated by the National Comprehensive Cancer Network 1, 2

Thymectomy is indicated in myasthenia gravis because removing the source of autoantibody production leads to remission or significant improvement in the majority of patients, as supported by evidence from Ophthalmology and the National Comprehensive Cancer Network 5, 1, 2
Thymectomy is always indicated when thymoma is present, regardless of myasthenia gravis status, according to the National Comprehensive Cancer Network and Ophthalmology 5, 1, 2
Sternotomy is the principal route of approach for thymectomy, as recommended by the British Journal of Cancer 6
Minimally invasive procedures are not typically recommended due to lack of long-term data on recurrence and survival, as stated by the National Comprehensive Cancer Network 2

Before any surgical procedure in patients with suspected thymoma, neurologist consultation and treatment optimization are mandatory if myasthenia gravis is present, as emphasized by the National Comprehensive Cancer Network 1, 2, 4
Symptoms requiring evaluation include drooping eyelids, double vision, drooling, difficulty climbing stairs, hoarseness, and dyspnea, as listed by the National Comprehensive Cancer Network 1, 2, 4
Treatment by an experienced neurologist must occur before surgical resection to prevent perioperative respiratory complications, as recommended by the National Comprehensive Cancer Network 1, 2